Related Experiment Videos
Astemizole-D causes less sleep impairment than loratadine-D
1Janssen Research Foundation, Beerse, Belgium.
The Journal of International Medical Research
|May 1, 1995
Summary
Astemizole-D, taken once daily, caused less sleep impairment than twice-daily loratadine-D in a study of 240 volunteers. Both allergy medications were well-tolerated with similar side effects.
Area of Science:
- Pharmacology
- Clinical Trials
- Sleep Medicine
Background:
- Allergic rhinitis treatments often impact sleep quality.
- Comparing antihistamine/decongestant formulations is crucial for patient care.
Purpose of the Study:
- To compare the tolerability of once-daily astemizole-D and twice-daily loratadine-D.
- To assess the impact of these treatments on sleep quality in healthy volunteers.
Main Methods:
- Randomized, double-blind, double-dummy, parallel-group trial.
- 240 healthy volunteers received either astemizole-D or loratadine-D for 3 days.
- Sleep quality parameters, including night-time waking and restlessness, were evaluated.
Main Results:
- Astemizole-D showed statistically significant improvements in sleep quality compared to loratadine-D.
- Fewer instances of night-time waking and restlessness were reported with astemizole-D.
- Both treatments were well-tolerated with no significant differences in adverse events or clinical cardiovascular effects.
Conclusions:
- Once-daily astemizole-D is a well-tolerated option for allergy symptom relief.
- Astemizole-D demonstrates a favorable impact on sleep quality compared to loratadine-D.
- Further research can explore long-term sleep benefits in patients with allergic rhinitis.